Amino acid metabolites for enhanced detoxification activity

The combination of ILA and IML in fermented infant formulas addresses the vulnerability of young children's detoxification systems by activating AhR and inducing CYP1A1, enhancing detoxification and reducing harmful substance exposure.

WO2024236095A1PCT designated stage expired Publication Date: 2024-11-21NV NUTRICIA
View PDF 18 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/063477
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-16
Filing Date
2024-05-16
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Infant and young children have a vulnerable detoxification system, making them susceptible to harmful xenobiotics and endogenous substances, with existing infant formulas lacking optimal composition to mimic the detoxification benefits of human milk.

Method used

A nutritional composition comprising a combination of indole lactic acid (ILA) and imidazole lactic acid (IML), produced through partial fermentation by lactic acid-producing bacteria like Bifidobacterium and Streptococcus, which activates the Aryl hydrocarbon Receptor (AhR) and induces cytochrome P450 1A1 expression, enhancing detoxification capacity.

Benefits of technology

The combination of ILA and IML in fermented infant formulas synergistically activates AhR and induces CYP1A1, improving detoxification capacity, reducing harmful effects from xenobiotics and bilirubin, and potentially treating elevated blood pressure and hypertension.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000028_0001
    Figure IMGF000028_0001
  • Figure IMGF000030_0001
    Figure IMGF000030_0001
  • Figure IMGF000030_0002
    Figure IMGF000030_0002
Patent Text Reader

Abstract

The invention pertains to a method for increasing and / or improving detoxification capacity comprising increasing AhR activity and / or increasing expression of CYP1A1 in a human subject comprising administering a combination of indole lactic acid (ILA) and imidazole lactic acid (IML), therapeutically effective combinations of ILA and IML for use in improving detoxification and a nutritional composition that comprises ILA and IML for use in improving detoxification.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] AMINO ACID METABOLITES FOR ENHANCED DETOXIFICATION ACTIVITY

[0002] FIELD OF THE INVENTION

[0003] The present invention relates to combinations and compositions for improving detoxification.

[0004] BACKGROUND OF THE INVENTION

[0005] The Aryl hydrocarbon Receptor (AhR) is a ligand-activated nuclear receptor and transcription factor that regulates genes involved in toxin metabolism. Upon ligand binding, AhR translocates to the nucleus where it dimerizes with ARNT forming a functional transcription factor that subsequently binds to dioxin response elements in the promotor of multiple genes. AhR thereby controls detoxification of xenobiotic or potentially harmful, endogenous substances by activating detoxification pathways through induction of target gene expression, e.g., of enzymes involved in detoxification processes. AhR plays a role in numerous tissues, including the liver, gut, and lungs.

[0006] The best explored downstream target of AhR is cytochrome P450 1A1 (CYP1A1), an enzyme that is involved in the phase I metabolism of harmful xenobiotic (e.g., drugs, environmental contaminants, pollutants) and endogenous (e.g., bilirubin) substances into less harmful compounds (Ye et al., The FEBS Journal, 2019). Exposure to xenobiotics occurs via multiple routes, for example orally via food (including human breast milk (Bernasconi et al., Global Pediatrics, 2022) and water that is used for preparation of infant formulas, via the skin and via the respiratory system (Calatayud Arroyo et al., Environmental Pollution, 2021).

[0007] Infants and children are more vulnerable to harmful compounds due to a lower capacity and immaturity of their innate detoxification system and immaturity of their immune system. All infants are born with an immature and therefore leaky gut and a child’s liver does not function at peak efficiency for the first 2 to 4 years of life (Grijalva et al., Seminars in Pediatric Surgery, 2013). Therefore, infants and young children are more susceptible to (permanent) damaging effects of exposure to toxins throughout the body, and these damaging effects may even give rise to permanent effects. Furthermore, infants, especially preterm babies, infants born by C-section and infants treated by antibiotics are even more vulnerable to toxins. These infants in addition may suffer from problems breaking down the endogenous compound bilirubin, leading to jaundice (Dong et al., Clinical and Translational Gastroenterology, 2018).

[0008] Several AhR agonists have been studied in recent years. Among these compounds their effects on gastrointestinal inflammation and the immune system have most widely been studied, yet their potential in improving detoxification remains largely unexplored. WO 2021 / 011481 discloses the use of indole-3- lactic acid (ILA) that interacts with AhR in intestinal epithelial cells for reducing inflammation in an infant's gastrointestinal tract. WO 2022 / 026450 discloses a method for treating a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or a combination thereof by modulating the gut microbiome composition or enzymatic activity of the subject including modulating indole production. US 2013 / 337105 describes a fermented infant formula which improves protein digestibility and is focussed on decreasing protein digestive effort by decreasing the amount of endogenously formed proteases. The document describes that the reduced formation of toxic metabolites is greatly due to the decreased amount of protein entering the colon.

[0009] Ehrlich et al., BMC Microbiology 2020, 20:357 (doi: 10.1186 / s12866-020-02023-y) describe an important role for B. infantis in producing ILA when human milk oligosaccharides are available. The authors do not mention imidazole lactic acid (IML) and attribute the anti-inflammatory effect of ILA to the activation of ArH and Nrf2 pathways. Epithelial cells exposed to ILA would produce less pro- inflammatory IL-8 and TNF-a providing a possible mechanism for anti-inflammatory effects.

[0010] Sen et al., Frontiers in Microbiology, 2023-04-13 (doi: 10.3389 / fmicb.2023.1155438) suggest a role for intestinal epithelial cells on the production of ILA by B. breve. ILA is seen as a beneficial metabolite for exerting anti-inflammatory activity via the AhR. The authors do not describe or investigate any effect of IML.

[0011] WO 2019 / 55718 discloses the use of compositions to increase output of particular metabolites in the gut of a nursing infant. These compositions generally comprise one or more bacterial strains selected for their growth on mammalian milk oligosaccharides and a source of mammalian milk oligosaccharides. Metabolomic analysis of infant feces shows ILA production in the gut of infants.

[0012] CN114317621 discloses Lactobacillus GDM1.140 metabolites. Focus is on heavy metal detoxification function of these metabolites. Cui Q et al, 2021 , J Agric Food Chem discloses the amelioration of DSS- induced colitis in mice by Bifidobacterium bifidum by regulating inflammasome pathways through Indole- 3-lactic acid production and AhR pathway activation in the colon of these mice.

[0013] Lamas B et al, 2020, Science Transl Med discloses that AhR ligand production by the gut microbiota is decreased in celiac disease and thereby leads to intestinal inflammation.

[0014] Meng et al, 2020, Ped Res 88:209-217 discloses that ILA, a breast milk tryptophan metabolite secreted by Bifidobacterium longum subspecies infantis, is a ligand for AhR in enterocytes and acts antiinflammatory in the immature intestine of infants. ILA was tested in an established human immature small intestinal cell line, necrotizing colitis enterocytes, and other immature human enterocytes for antiinflammatory effects.

[0015] Human milk is the preferred food for infants providing several bioactive factors that benefit the health and the lower capacity of the detoxification system of neonates early in life. However, it is not always possible or desirable to breastfeed an infant. In such cases infant formulas or follow-on formulas are a good alternative. These formulas should have an optimal composition in order to mimic the beneficial effects of human milk as close as possible.

[0016] There remains a need in the art for synthetic nutritional compositions such as infant formulas and follow- on formulas that promote the activation of detoxification pathways.

[0017] SUMMARY OF THE INVENTION

[0018] The inventors found that infant formulas that were partly fermented by lactic acid producing bacteria were found to contain higher levels of indole lactic acid (ILA) and imidazole lactic acid (IML) when compared to non-fermented infant formulas. The level of IML in the fermented infant formula was closer to the level of human milk. It was observed that ILA, but not IML, activates the Aryl hydrocarbon Receptor (AhR) and is able to induce cytochrome P450 1A1 (CYP1A1) expression, thereby activating the detoxification system. Surprisingly, a synergistic effect on the activation of the AhR and induction of CYP1 A1 was observed when a combination of both ILA and IML were present.

[0019] These results are indicative of a beneficial effect of nutritional compositions comprising ILA and IML for detoxification capacity. This may be especially beneficial to prevent detrimental effects in infants and young children due to exposure to environmental xenobiotics such as aromatic hydrocarbons like polycyclic aromatic hydrocarbons or due to increased levels of harmful endogenous substances like bilirubin.

[0020] LIST OF FIGURES

[0021] The present invention will be discussed in more detail below, with reference to the attached figures.

[0022] Figure 1. A. ILA measurements in different infant formulas; B. IML measurements in different infant formulas.

[0023] Figure 2. MeBio equivalent AhR activation measurements by the treatments of interest: ILA 1 mM, IML 1 mM and the combination ILA 1 mM + IML 1 mM.

[0024] LIST OF PREFERRED EMBODIMENTS

[0025] 1 . A method for increasing and / or improving detoxification capacity in a human subject comprising administering a combination of indole lactic acid (ILA) and imidazole lactic acid (IML).

[0026] 2. The method according to embodiment 1 wherein increasing and / or improving detoxification capacity in a human subject involves increasing AhR activity and / or increasing expression of CYP1A1.

[0027] 3. The method according to embodiments 1 and 2 wherein the combination of ILA and IML is comprised in a nutritional composition.

[0028] 4. The method according to embodiment 3 wherein the nutritional composition comprises lactic acid producing bacteria, preferably selected from the group consisting of Bifidobacterium and Streptococcus, more preferably S. thermophilus, B. breve, B. longum spp longum, B. bifidum and / or B.longum spp infantis, most preferably B. breve. 5. The method according to embodiment 3 or 4 wherein the nutritional composition is at least partly fermented by lactic acid producing bacteria, preferably comprising 0.1 to 1 .5 wt percent of the sum of lactic acid and lactate based on dry weight of the composition.

[0029] 6. The method according to embodiment 5 wherein the nutritional composition is fermented by lactic acid producing bacteria, preferably selected from the group consisting of Bifidobacterium and Streptococcus, more preferably S. thermophilus, B. breve, B. longum spp longum, B. bifidum and / or B. longum spp infantum, most preferably B. breve, and wherein preferably the lactic acid producing bacteria are inactivated after fermentation.

[0030] 7. The method according to embodiments 3 to 6 wherein the nutritional composition comprises

[0031] 2.5 to 15 wt percent non-digestible oligosaccharides based on dry weight of the nutritional composition and the non-digestible oligosaccharides are selected from the group consisting of fructo-oligosaccharides, non-digestible dextrins, galacto-oligosaccharides, xylo-oligosaccharides, arabino-oligosaccharides, arabinogalacto- oligosaccharides, gluco-oligosaccharides, gentio- oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, mannanoligosaccharides, isomalto-oligosaccharides, nigero-oligosaccharides, chito-oligosaccharides, soy oligosaccharides, uronic acid oligosaccharides, N-acetylated oligosaccharides, sialyl- oligosaccharides and fuco-oligosaccharides, and mixtures thereof, preferably galactooligosaccharides and fructo-oligosaccharides.

[0032] 8. The method according to embodiments 3 to 7 wherein the nutritional composition comprises at least one long chain poly-unsaturated fatty acid [LC-PUFA], preferably at least two LC-PUFAs, selected from the group consisting of DHA, EPA and ARA

[0033] 9. The method according to embodiments 3 to 8 wherein the combination of ILA and IML is comprised in a nutritional composition and the nutritional composition is an infant formula or a follow-on formula.

[0034] 10. The method according to the preceding embodiments wherein the human subject is a healthy, term infant or young child.

[0035] 11 . The method according to the preceding embodiments wherein detoxification capacity is increased and / or improved compared to human subjects not being administered a combination of ILA and IML.

[0036] 12. The method according to the preceding embodiments wherein increasing and / or improving detoxification capacity occurs in the gastrointestinal tract of said human subject.

[0037] 13. A therapeutically effective combination of indole lactic acid (ILA) and imidazole lactic acid (IML) for use in a. mitigating harmful effects caused by toxins, in particular aromatic hydrocarbons in a human subject; b. increasing and / or improving detoxification capacity in a human by activating the AhR; c. increasing and / or improving detoxification capacity in a human subject by increasing CYP1A1 expression; d. improving bilirubinemia.

[0038] 14. A nutritional composition comprising a combination of indole lactic acid (ILA) and imidazole lactic acid (IML) for use in a. mitigating harmful effects caused by toxins, in particular aromatic hydrocarbons in a human subject; b. increasing and / or improving or increasing detoxification capacity in a human by activating the AhR; c. increasing and / or improving detoxification capacity in a human subject by increasing CYP1A1 expression; d. improving bilirubinemia e. treating and / or improving elevated blood pressure and / or hypertension compared to human subject being administered a nutritional composition that does not comprise ILA and IML.

[0039] 15. The nutritional composition for use according to embodiment 14 wherein the nutritional composition comprises lactic acid producing bacteria, preferably selected from the group consisting of Bifidobacterium and Streptococcus, more preferably S. thermophilus, B. breve, B. longum spp longum, B. bifidum and / or B. longum spp infantis, most preferably B. breve.

[0040] 16. The nutritional composition for use according to embodiments 14 to 15 wherein the nutritional composition is at least partly fermented by lactic acid producing bacteria, preferably comprising 0.1 to 1 .5 wt percent of the sum of lactic acid and lactate based on dry weight of the composition and / or preferably comprising tryptophan and histidine.

[0041] 17. The nutritional composition for use according to embodiment 16, wherein the nutritional composition comprises tryptophan and histidine and is at least partially fermented by Bifidobacterium and optionally by Streptococcus thermophilus, preferably a Bifidobacterium selected from B. breve, B. longum spp infantis, B. bifidum and B. longum spp infantis, most preferably B. breve and wherein preferably the lactic acid producing bacteria are inactivated after fermentation.

[0042] 18. The nutritional composition for use according to embodiments 14 - 17 wherein the composition further comprises non-digestible oligosaccharides selected from the group consisting of fructooligosaccharides, non-digestible dextrins, galacto-oligosaccharides, xylo-oligosaccharides, arabino-oligosaccharides, arabinogalacto-oligosaccharides, gluco-oligosaccharides, gentio- oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, mannanoligosaccharides, isomalto-oligosaccharides, nigero-oligosaccharides, chito-oligosaccharides, soy oligosaccharides, uronic acid oligosaccharides, N-acetylated oligosaccharides, sialyloligosaccharides and fuco-oligosaccharides, and mixtures thereof preferably the non- digestible oligosaccharide are GOS and / or FOS.

[0043] 19. The nutritional composition for use according to embodiments 14 to 18 wherein the nutritional composition comprises at least one long chain poly-unsaturated fatty acid [LC-PUFA], preferably at least two LC-PUFAs, selected from the group consisting of DHA, EPA and ARA.

[0044] 20. The nutritional composition for use according to embodiments 14 to 19 wherein the nutritional composition is selected from an infant formula and a follow-on formula.

[0045] 21. The nutritional composition for use according to embodiments 14 to 20, wherein improving and / or increasing detoxification capacity involves AhR activation and / or CYP1 A1 expression induction. 22. The nutritional composition for use according to embodiments 13 to 21 , wherein improving and / or increasing detoxification capacity occurs in the gastrointestinal tract of said human.

[0046] 23. The nutritional composition for use according to embodiments 13 to 22, wherein the nutritional composition is administered to an infant or young child, preferably an infant, more preferably to a preterm infant, C section born infant or infants that received antibiotics.

[0047] 24. The nutritional composition for use according to embodiments 13-23, wherein the nutritional composition is administered to a human subject with a high exposure to xenobiotic or harmful endogenous substances.

[0048] 25. A therapeutically effective combination of indole lactic acid (ILA) and imidazole lactic acid (IML) or nutritional composition comprising a combination of ILA and IML for use in treating and / or preventing elevated blood pressure and / or hypertension, preferably in an adult subject.

[0049] 26. The therapeutically effective combination of Ila and IML or nutritional composition comprising a combination of ILA and IML for use according to embodiment 25, wherein the therapeutically effective combination is comprised in a nutritional composition and wherein the nutritional composition comprises at least one long chain poly-unsaturated fatty acid [LC-PUFA], preferably at least two LC-PUFAs, selected from the group consisting of DHA, EPA and ARA.

[0050] 27. Method for increasing AhR activity and / or increasing expression of CYP1A1 in a human subject.

[0051] DETAILED DESCRIPTION OF THE INVENTION

[0052] The present invention concerns a method, in particular a non-therapeutic method, for increasing and / or improving detoxification capacity in a human subject comprising administering a combination of indole lactic acid (ILA) and imidazole lactic acid (IML). The improvement in detoxification capacity is as compared to a subject not administered said combination of ILA and IML. In an aspect of the invention the method concerns inducing an improvement in detoxification capacity more similar to the detoxification capacity observed in human milk fed infants. The improvement in detoxification capacity involves increasing AhR activity and / or increasing expression of CYP1A1. In a preferred aspect the present method involves administering said combination of ILA and IML in a nutritional composition, preferably a nutritional composition that is at least partly fermented by lactic acid producing bacteria. In a further preferred aspect, the method involves administering the combination of ILA and IML to a healthy, term infant or young child. The invention accordingly also pertains to a method for increasing AhR activity and / or increasing expression of CYP1A1 in a human subject.

[0053] For some jurisdictions this can also be worded as the use of a combination of ILA and IML for increasing and / or improving detoxification capacity, in particular non-therapeutically increasing and / or improving detoxification capacity, in a human subject, preferably a healthy, term infant or young child. Preferably the improvement in detoxification capacity involves increasing AhR activity and / or increasing expression of CYP1A1.

[0054] In other words, the invention thus concerns the use of a combination of ILA and IML in the manufacture of a nutritional composition for increasing and / or improving detoxification capacity in a human subject, preferably a healthy, term infant or young child. Preferably the improvement in detoxification capacity involves increasing AhR activity and / or increasing expression of CYP1A1 .

[0055] The invention further pertains to a therapeutically effective combination of ILA and IML and a nutritional composition comprising a therapeutically effective combination of ILA and IML for therapeutic use in a. mitigating harmful effects caused by toxins, in particular aromatic hydrocarbons in a human subject; b. improving and / or increasing detoxification capacity in a human by activating the AhR; c. improving and / or increasing detoxification capacity in a human subject by increasing CYP1A1 expression; d. improving bilirubinemia.

[0056] In a preferred aspect the therapeutically effective combination of ILA and IML for the therapeutic uses is contained in a nutritional composition. The nutritional composition comprising a therapeutically effective combination of ILA and IML is selected from an infant formula and a follow-on formula. In some aspects said composition is at least partly fermented by lactic acid producing bacteria. In an embodiment said nutritional composition for therapeutic use is administered to an infant or young child, preferably an infant, more preferably to a preterm, very low birth weight infant, C-section born infant and / or antibiotic treated infant.

[0057] Accordingly, the present invention provides for a nutritional composition comprising lipid, protein, digestible carbohydrates, and therapeutically effective combination of ILA and IML, wherein the nutritional composition is selected from an infant and follow-on formula, wherein said nutritional composition is not human milk. In some aspects of the invention the nutritional composition is at least partly fermented by lactic acid producing bacteria.

[0058] The therapeutic increase and / or improvement in detoxification capacity is as compared to a subject not administered said combination of ILA and IML. In an aspect of the invention the method may concern inducing an increase and / or improvement in detoxification capacity more similar to the detoxification capacity as observed in human milk fed infants.

[0059] The invention also pertains to a nutritional composition comprising lipid, protein, digestible carbohydrates, and therapeutically effective combination of ILA and IML, wherein the nutritional composition is selected from an infant and follow-on formula, wherein said nutritional composition is not human milk and wherein the nutritional composition is optionally at least partly fermented by lactic acid producing bacteria for therapeutic use in a. mitigating harmful effects caused by toxins, in particular aromatic hydrocarbons in a human subject; b. improving and / or increasing detoxification capacity in a human by activating the AhR; c. improving and / or increasing detoxification capacity in a human subject by increasing CYP1A1 expression; d. improving bilirubinemia.

[0060] For some jurisdictions the invention can also be worded as the use of a therapeutically effective combination of ILA and IML for the manufacture of a nutritional composition for use in a. mitigating harmful effects caused by toxins, in particular aromatic hydrocarbons in a human subject; b. improving and / or increasing detoxification capacity in a human by activating the AhR; c. improving and / or increasing detoxification capacity in a human subject by increasing CYP1A1 expression; d. improving bilirubinemia, preferably in an infant or young child.

[0061] In some embodiments the invention also involves a therapeutically effective combination ILA and IML or nutritional composition comprising a combination of ILA and IML for use in treating and / or preventing elevated blood pressure and / or hypertension, preferably in an adult subject. Alternatively worded the invention may also pertain to the use of a therapeutically effective combination of ILA and IML for the manufacture of a nutritional composition for use in treating and / or preventing elevated blood pressure and / or hypertension, preferably in an adult subjec

[0062] Definitions

[0063] Throughout this application and as used herein, the following terms have the following meanings.

[0064] An infant is a child under the age of 12 months.

[0065] “Infant formula” or “follow-on formula” or “young child formula” means that it concerns a composition that is artificially made or in other words that it is a synthetic composition (i.e., the synthetic composition is not breast milk). Hence the nutritional composition that is administered is an artificial infant formula or an artificial follow-on formula or an artificial young child formula or a synthetic infant formula or a synthetic follow-on formula or a synthetic young child formula. Infant formula refers to nutritional compositions, artificially made, intended for infants of 0 months to about 4 months to 6 months of age and are intended as a substitute for human milk. Typically, infant formulas are suitable to be used as sole source of nutrition. Such infant formulas are also known as starter formula.

[0066] Follow-on formulas are for infants starting with at 4 months to 6 months of life to 12 months of life and are intended to be supplementary feedings for infants that start weaning on other foods. Infant formulas and follow-on formulas are subject to strict regulations, for example for the EU regulations no. 609 / 2013 and no. 2016 / 127.

[0067] A young child is a child aged between one and three years, also called a toddler. Young child formula refers to nutritional compositions, artificially made, intended for children of 1 to 3 years of age, which are intended to be supplementary feedings for infants.

[0068] "Nutritional composition" means a substance or formulation that satisfies at least a portion of a subject's nutrient requirements.

[0069] The nutritional composition according to the present invention is preferably selected from an infant formula, a follow-on formula, and a growing-up milk. This means that the present nutritional composition is not human milk. Alternatively, the term "formula" means that it concerns a composition that is artificially made or in other words that it is synthetic. Hence in one embodiment the nutritional composition is selected from an artificial infant formula, an artificial follow-on formula and an artificial growing-up milk or a synthetic infant formula, a synthetic follow-on formula and a synthetic growing-up milk.

[0070] The term “hypertension” refers to abnormally high arterial blood pressure, when compared to prior blood pressure readings, and the abnormally high value is maintained over a specified time period. Conventionally, the time period is 3-6 months. The increase may be observed in systolic pressure, diastolic pressure, or both. Conventionally, hypertension is defined as a blood pressure of equal to or greater than 140 / 90 mm Hg. Blood pressure may be measured by any method known in the art. Such methods include, but are not limited to direct arterial puncture, oscillometry, Doppler ultrasonography, and a sphygmomanometer. In a preferred embodiment, blood pressure is measured with a sphygmomanometer. While the person taking the measurement listens to the pulse of the patient and watches the sphygmomanometer gauge, two measurements (systolic pressure and diastolic pressure) are recorded. Blood pressure is measured in millimeters of mercury (mm Hg).

[0071] As used herein, a "therapeutically effective amount" is an amount that reduces symptoms, manages, increases, or induces detoxification or provides a nutritional, physiological, or medical benefit associated therewith to the individual.

[0072] In this document and in its claims, the verb "to comprise" and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the elements is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one".

[0073] ILA and IML lndole-3-lactic acid (ILA) as used herein can also be referred to as p-(3-indolyl)lactic acid, 2-hydroxy-3- (3-indolyl)propanoic acid, 3-(3-indolyl)-2-hydroxypropanoic acid, 3-indolyllactic acid, and indole lactic acid. ILA can be produced chemically and is commercially available for instance at Sigma Aldrich and MolPort. ILA is a metabolite of tryptophan breakdown and is known to play a beneficial role in mitigating inflammation and maintaining intestinal epithelial barrier integrity. ILA is also known to be a metabolite produced by Bifidobacteria when metabolizing tryptophan. Imidazole lactic acid (IML) as used herein can also be referred to as 3-(imidazol-1-yl)lactic acid, 2- hydroxy-3-imidazol-1-ylpropanoic acid, 1 -imidazolelactic acid, 2-hydroxy-3-(1 H-imidazol-1-yl)propanoic acid, imidazole-3-lactic acid. IML can be produced chemically and is commercially available for instance at Sigma Aldrich. IML is also known to be a metabolite produced by bacteria when metabolizing histidine.

[0074] It was found by the inventors that infant formulas fermented by lactic acid producing bacteria contained both IML and ILA, whereas it was absent in infant formulas that were not at least partially fermented. It was also found that in human milk IML is present.

[0075] In an aspect of the invention ILA and IML may be derived from a bacterial species, preferably a Bifidobacterium. In an embodiment such exogenous derived ILA and IML may be administered in combination with each other or preferably added to a nutritional composition. ILA and IML may also be comprised in a nutritional composition as part of by the final nutritional composition comprises 5 to 97.5 wt% of a fermented composition.

[0076] The present nutritional composition preferably comprises 0.001 to 0.6 wt% ILA, more preferably 0.02 to 0.5 wt%, even more preferably 0.005 to 0.4 wt%, most preferably 0.008 to 0.35 wt%, based on dry weight of the nutritional composition. Based on 100 ml the present nutritional composition preferably comprises 0.25 to 200 mg ILA, more preferably 1 .25 to 150 mg, even more 2.5 to 100 mg based on 100 ml of the nutritional composition. Based on 100 kcal the nutritional composition preferably comprises 0.3 to 300 mg ILA, more preferably 1.8 to 225 mg, even more preferably 3.5 to 150 mg based on 100 kcal of the nutritional composition.

[0077] The present nutritional composition preferably comprises 0.001 to 0. 6 wt% IML, more preferably 0.002 to 0.5 wt%, even more preferably 0.005 to 0.4 wt%, most preferably 0.008to 0.35 wt%, based on dry weight of the nutritional composition. Based on 100 ml the present nutritional composition preferably comprises 0.25 to 200 mg IML, more preferably 1.25 to 150 mg, even more preferably 2.5 to 100 mg based on 100 ml of the nutritional composition. Based on 100 kcal the nutritional composition preferably comprises 0.3 to 300 mg IML, more preferably 1 .8 to 225 mg, even more preferably 3.5 to 150 mg based on 100 kcal of the nutritional composition.

[0078] Preferably the nutritional compositions comprise 0.001 to 0.6 wt% of ILA and 0.001 to 0.6 wt% of IML based on dry weight of the nutritional composition. Alternatively worded the nutritional composition preferably comprises 0.25 to 200 mg ILA and 0.25 to 200 mg IML based on 100 ml of the nutritional composition. Also, the nutritional composition preferably comprises 0.3 to 300 mg ILA and 0.3 to 300 mg IML per 100 kcal of the nutritional composition. Fermented composition

[0079] Preferably ILA and IML are present in a nutritional composition that is at least party fermented. The nutritional composition in the methods or compositions for uses according to the present invention, hereafter also referred to as the present nutritional composition, or nutritional composition of the invention or final nutritional composition, is thus at least party fermented. A partly fermented nutritional composition comprises at least for a part a composition that was fermented by lactic acid producing bacteria.

[0080] The fermentation preferably takes place during the production process of the nutritional composition. Preferably, the nutritional composition does not contain significant amounts of viable bacteria in the final product, and this can be achieved by heat inactivation after fermentation or inactivation by other means. Preferably the fermented composition is a milk-derived product, which is a milk substrate that is fermented by lactic acid producing bacteria, preferably Bifidobacteria, wherein the milk substrate comprises at least one selected from the group consisting of milk, milk-derived carbohydrates, whey, whey protein, whey protein hydrolysate, casein, casein hydrolysate or mixtures thereof. Suitably, nutritional compositions comprising fermented compositions and their way of producing them are described in WO 2009 / 151330, WO 2009 / 151331 and WO 2013 / 187764.

[0081] The fermented composition comprises post-biotics produced by the lactic acid producing bacteria. Postbiotics are functional bioactive compounds, generated in a matrix during fermentation, which may be used to promote health. The term postbiotics can be regarded as an umbrella term for all synonyms and related terms of these microbial fermentation components. Therefore, postbiotics can include many different constituents including metabolites, short-chain fatty acids (SCFAs), microbial cell fractions, functional proteins, extracellular polysaccharides (EPS), cell lysates, teichoic acid, peptidoglycanderived muropeptides and pili-type structures. A composition comprising such post-biotics is thought to be advantageously closer to breast milk, as breast milk is not a clean synthetic formula, but contains metabolites, bacterial cells, cell fragments and the like.

[0082] It was found that the postbiotics of the fermented composition also comprised ILA and IML. The inventors now found that that specifically the combination of the postbiotic metabolites IML and ILA resulted in beneficially activating AhR and inducing CYP1A1. Therefore, the fermented composition, in particular a fermented milk-derived product, comprising IML and ILA has an improved effect compared to non-fermented milk-derived product on activating AhR and inducing CYP1A1.

[0083] Preferably the final nutritional composition comprises 5 to 97.5 wt% of the fermented composition based on dry weight, more preferably 10 to 90 wt%, more preferably 20 to 80 wt%, even more preferably 25 to 60 wt%. As a way to specify that the final nutritional composition comprises at least partly a fermented composition, and to specify the extent of fermentation, the level of the sum of lactic acid and lactate in the final nutritional composition can be taken as a marker, as this is the metabolic end product produced by the lactic acid producing bacteria upon fermentation. This is then also indicative of the amounts of ILA and IML present in the composition. The present final nutritional composition preferably comprises 0.1 to 1.5 wt% of the sum of lactic acid and lactate based on dry weight of the composition, more preferably 0.1 to 1 .0 wt%, even more preferably 0.2 to 0.5 wt%. Preferably at least 50 wt%, even more preferably at least 90 wt%, of the sum of lactic acid and lactate is in the form of the L(+)-isomer. Thus in one embodiment the sum of L(+)-lactic acid and L(+)-lactate is more than 50 wt%, more preferably more than 90 wt%, based on the sum of total lactic acid and lactate. Herein L(+)-lactate and L(+)-lactic acid is also referred to as L-lactate and L-lactic acid.

[0084] Lactic acid producing bacteria used for producing the fermented ingredient

[0085] Lactic acid producing bacteria used for preparing the fermented ingredient, in particular for fermentation of the milk substrate are preferably provided as a mono- or mixed culture. Lactic acid producing bacteria consists of the genera Bifidobacterium, Lactobacillus, Carnobacterium, Enterococcus, Lactococcus, Leuconostoc, Oenococcus, Pediococcus, Streptococcus, Tetragenococcus, Vagococcus and Weissella. Preferably the lactic acid producing bacteria used for fermentation comprises bacteria of the genus Bifidobacterium, more preferably Bifidobacteria species that are found in breast fed infants as these are known to produce the highest level of ILA (Laursen et al. Nature microbiology, 2021), such as B. breve, B. longum spp longum, B. longum spp infantis, and B. bifidum.

[0086] Preferably the lactic acid producing bacteria used for fermentation comprises, or is, at least one Bifidobacterium selected from the group consisting of B. breve, B. longum spp infantis, B. bifidum, B. longum spp longum. Such bifidobacteria are typically found in the microbiota of human infants and were found to be able to product ILA to higher amounts (Sukurai et al., 2019). More preferably the lactic acid producing bacteria used for fermentation comprises or is at least one selected from B. breve, more preferably B. breve selected from the group consisting of B. breve Bb-03 (Rhodia / Danisco), B. breve M- 16V (Morinaga), B. breve R0070 (Institute Rosell, Lallemand), B. breve BR03 (Probiotical), B. breve BR92 (Cell Biotech) DSM 20091 , LMG 11613, B breve CNCM 1-5177 deposited under the Budapest Treaty at the Collection Nationale de Cultures de Microorganism [CNCM], at Institut Pasteur, 25 Rue du Dr Roux, Paris, France on 9 March 2017 by Compagnie Gervais Danone and B. breve C50 deposited under deposit number 1-2219 at the CNCM, at Institut Pasteur, 25 Rue du Dr Roux, Paris, France on 31 May 1999 by Compagnie Gervais Danone and published in US patent 7,410,653. Most preferably, the B. breve is B. breve M-16V (Morinaga), B. breve 1-5177 or B. breve 1-2219.

[0087] Preferably the fermented composition is fermented by Bifidobacterium and Streptococcus. Selection of a suitable strain of S. thermophilus is described in example 2 of EP 778885 and in example 1 of FR 2723960.

[0088] Preferred strains of S. thermophilus to prepare the fermented ingredient for the purpose of the present invention have been deposited by Compagnie Gervais Danone at CNCM run by the Institut Pasteur, 25 rue du Docteur Roux, Paris, France on 23 August 1995 under the accession number 1-1620 and on 25 August 1994 under the accession number 1-1470. Other S. thermophilus strains are commercially available.

[0089] Most preferably the nutritional composition of the invention comprises fermented composition that is fermented by lactic acid producing bacteria comprising both B. breve and S. thermophilus. In one embodiment the fermentation by lactic acid producing bacteria is fermentation by Streptococcus thermophilus and Bifidobacterium breve. In one embodiment, the final nutritional composition comprises fermented composition wherein the lactic acid producing bacteria are inactivated after fermentation.

[0090] Preferably the fermented composition is not fermented by Lactobacillus bulgaricus. L. bulgaricus fermented products are considered not suitable for infants, since in young infants the specific dehydrogenase that converts D-lactate to pyruvate is far less active than the dehydrogenase which converts L-lactate.

[0091] Preferably the nutritional composition of the invention comprises inactivated lactic acid producing bacteria being the equivalent of more than 1x104cfu lactic acid producing bacteria per g based on dry weight of the final composition, more preferably 1x105cfu, even more preferably 1x106cfu. Preferably the inactivated bacteria or bacterial fragments are the equivalent of less than 1x1013cfu lactic acid producing bacteria per g based on dry weight of the final composition, more preferably 1x1011cfu, even more preferably 1x1010cfu. The correlation of inactivated lactic acid producing bacteria and the equivalence with cfu can be determined by molecular techniques, known in the art, or by checking the production process.

[0092] In some aspects of the present invention, the nutritional composition comprises 104-107cfu living lactic acid producing bacteria per g dry weight of the final nutritional composition, preferably 104-106cfu living bacteria of living lactic acid producing bacteria per g dry weight of the final nutritional composition.

[0093] Fermentation

[0094] Preferably the fermented composition is a milk-derived product, which is a milk substrate that is fermented by lactic acid producing bacteria and said milk substrate comprising at least one selected from the group consisting of milk, whey, whey protein, whey protein hydrolysate, casein, casein hydrolysate or mixtures thereof. The milk derived product or milk substrate to be fermented is suitably present in an aqueous medium. The milk substrate to be fermented comprises at least one selected from the group consisting of milk, milk-derived carbohydrates, whey, whey protein, whey protein hydrolysate, casein, casein hydrolysate or mixtures thereof. Milk can be whole milk, semi-skimmed milk and / or skimmed milk. Preferably the milk substrate to be fermented comprises skimmed milk. Whey can be sweet whey, and / or acid whey. Preferably the whey is present in a concentration of 3 to 80 g dry weight per I aqueous medium containing milk substrate, more preferably 40 to 60 g per I. Preferably whey protein hydrolysate is present in 2 to 80 g dry weight per I aqueous medium containing milk substrate, more preferably 5 to15 g / l. Such sources comprise proteins that contain the amino acids tryptophan and histidine. The bifidobacteria species as also found in the faeces of breast fed infant will metabolize the tryptophan and histidine to the ILA and IML, respectively. Preferably lactose is present in 5 to 50 g dry weight per I aqueous substrate, more preferably 1 to 30 g / l. Preferably the aqueous medium containing milk substrate comprises buffer salts in order to keep the pH within a desired range. Preferably sodium or potassium dihydrogen phosphate is used as buffer salt, preferably in 0.5 to 5 g / l, more preferably 1 .5 to 3 g per I. Preferably the aqueous medium containing milk substrate comprises cysteine in amount of 0.1 to 0.5 g per I aqueous substrate, more preferably 0.2 to 0.4 g / l. The presence of cysteine results in low redox potential of the substrate which is advantageous for activity of lactic acid producing bacteria, particularly bifidobacteria. Preferably the aqueous medium containing milk substrate comprises yeast extract in an amount of 0.5 to 5 g / l aqueous medium containing milk substrate, more preferably 1 .5 to 3 g / l. Yeast extract is a rich source of enzyme co-factors and growth factors for lactic acid producing bacteria. The presence of yeast extract will enhance the fermentation by lactic acid producing bacteria.

[0095] Suitably the milk substrate, in particular the aqueous medium containing milk substrate, is pasteurised before the fermentation step, in order to eliminate the presence of unwanted living bacteria. Suitably the product is pasteurised after fermentation, in order to inactivate enzymes. Suitably the enzyme inactivation takes place at 75 °C for 3 min. Suitably the aqueous medium containing milk substrate is homogenised before and / or the milk-derived product is homogenised after the fermentation. Homogenisation results in a more stable substrate and / or fermented product, especially in the presence of fat.

[0096] The inoculation density is preferably between 1x102to 5x1010, preferably between 1x104to 5x109cfu lactic acid producing bacteria / ml aqueous medium containing milk substrate, more preferably between 1x107to 1x109cfu lactic acid producing bacteria / ml aqueous medium containing milk substrate. The final bacteria density after fermentation is preferably between 1x103to 1x101°, more preferably between 1x104to 1x109cfu / ml aqueous medium containing milk substrate.

[0097] The fermentation is preferably performed at a temperature of approximately 20 °C to 50 °C, more preferably 30 °C to 45 °C, even more preferably approximately 37 °C to 42 °C. The optimum temperature for growth and / or activity for lactic acid producing bacteria, more particularly lactobacilli and / or bifidobacteria is between 37 °C and 42 °C.

[0098] The incubation is preferably performed at a pH of 4 to 8, more preferably 6 to 7.5. This pH does not induce protein precipitation and / or an adverse taste, while at the same time lactic acid producing bacteria such as lactobacilli and / or bifidobacteria are able to ferment the milk substrate.

[0099] The incubation time preferably ranges from 10 minutes to 48 h, preferably from 2 h to 24 h, more preferably from 4 h to 12 h. A sufficient long time enables fermentation and the concomitant production of ILA and IML and other postbiotics to take place at a sufficient or higher extent, whereas the incubation time needs not be unnecessarily long for economic reasons. Preferably, a milk derived product or milk substrate, preferably skimmed milk, is pasteurized, cooled, and fermented with one or more lactic acid producing strains, preferably a strain of S. thermophilus, to a certain degree of acidity, upon which the fermented product is cooled and stored. Preferably a second milk-derived product is prepared in a similar way using one or more Bifidobacterium species for fermentation. Subsequently, the two fermented products are preferably mixed together and mixed with other components making up an infant formula, except the fat component. Preferably, the mixture is preheated, and subsequently fat is added in-line, homogenized, pasteurized, and dried. Alternatively, the fermentation takes place having both Bifidobacterium, preferably B. breve, and S. thermophilus in the fermentation tank.

[0100] Procedures to prepare fermented composition suitable for the purpose of the present invention are known per se. EP 778885, which is incorporated herein by reference, discloses in particular in example 7 a suitable process for preparing a fermented ingredient. FR 2723960, which is incorporated herein by reference, discloses in particular in example 6 a suitable process for preparing a fermented ingredient. Briefly, a milk substrate, preferably pasteurised, containing lactose and optionally further macronutrients such as fats, preferably vegetable fats, casein, whey protein, vitamins and / or minerals etc. is concentrated, e.g., to between 15 to 50% dry matter and then inoculated with S. thermophilus, for example with 5% of a culture containing 106to 1010bacteria per ml. Preferably this milk substrate comprises milk protein peptides. Temperature and duration of fermentation are as mentioned above. Suitably after fermentation the fermented ingredient may be pasteurised or sterilized and for example spray dried or lyophilised to provide a form suitable to be formulated in the end product.

[0101] A preferred method for preparing the fermented composition to be used in the nutritional composition of the invention is disclosed in WO 01 / 01785, more particular in examples 1 and 2. A preferred method for preparing the fermented composition to be used in the nutritional composition of the invention is described in WO 2004 / 093899, more particularly in example 1 . A further preferred method for preparing the fermented composition to be used in the nutritional composition of the invention is described in WO 2014 / 168474, more in particular in example 1 thereof.

[0102] Living cells of lactic acid producing bacteria in the fermented composition are after fermentation preferably eliminated, for example by inactivation and / or physical removal. The cells are preferably inactivated. Preferably the lactic acid producing bacteria are heat killed after fermentation of the milk substrate. Preferable ways of heat killing are (flash) pasteurization, sterilization, ultra-high temperature treatment, high temperature / short time heat treatment, and / or spray drying at temperatures bacteria do not survive. Cell fragments are preferably obtained by heat treatment. With this heat treatment preferably at least 90 % of living microorganisms are inactivated, more preferably at least 95 %, even more preferably at least 99 %. Preferably the fermented nutritional composition comprises less than 1x105colony forming units (cfu) living lactic acid producing bacteria per g dry weight of the final nutritional composition. The heat treatment preferably is performed at a temperature ranging from 70 to180 °C, preferably from 80 to 150 °C, preferably for about 3 minutes to 2 hours, preferably in the range of 80 to 140 °C for 5 minutes to 40 minutes. Inactivation of the lactic acid producing bacteria advantageously results in less post acidification and a safer product. This is especially advantageous when the nutritional composition is to be administered to infants or toddlers. Suitably after fermentation the fermented ingredient may be pasteurised or sterilized and for example spray dried or lyophilised to provide a form suitable to be formulated in the end product.

[0103] Non-digestible oligosaccharides

[0104] The present nutritional composition preferably comprises non-digestible oligosaccharides and more preferably comprises at least two different non-digestible oligosaccharides, in particular two different sources of non-digestible oligosaccharides. It is believed that the presence of non-digestible oligosaccharides will help stimulate the growth of endogenous bifidobacteria present in the colon and subsequently increase the production of ILA and IML in the colon. A mixture of two different non- digestible oligosaccharides will result in an improved effect on bifidobacteria, and hence ILA and IML production in the colon.

[0105] While ILA and IML present in the nutritional composition will exert their effect mainly in the small intestine, the endogenous bifidobacterial fermentation in the colon will advantageously result in additional ILA and IML production. As a result, it is believed that AhR activation and CYP1 A1 induction is achieved across both the small intestine and colon.

[0106] The term “oligosaccharides” as used herein refers to saccharides with a degree of polymerization (DP) of 2 to 250, preferably a DP 2 to 100, more preferably 2 to 60, even more preferably 2 to 10. If oligosaccharide with a DP of 2 to 100 is included in the present nutritional composition, this results in compositions that may contain oligosaccharides with a DP of 2 to 5, a DP of 50 to 70 and a DP of 7 to 60. The term “non-digestible oligosaccharides” as used in the present invention refers to oligosaccharides which are not digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract, e.g., small intestine and stomach, but which are preferably fermented by the human intestinal microbiota. For example, sucrose, lactose, maltose and maltodextrins are considered digestible.

[0107] Preferably the present non-digestible oligosaccharides are soluble. The term "soluble" as used herein, when having reference to a polysaccharides, fibres or oligosaccharides, means that the substance is at least soluble according to the method described by L. Prosky et al., J. Assoc. Off. Anal. Chem. 71 , 1017- 1023 (1988).

[0108] The non-digestible oligosaccharides included in the present nutritional compositions in the methods or uses according to the present invention preferably include a mixture of different non-digestible oligosaccharides. The non-digestible oligosaccharides are preferably at least one, more preferably at least two, selected from the group consisting of fructo-oligosaccharides, non-digestible dextrins, galactooligosaccharides, xylo-oligosaccharides, arabino-oligosaccharides, arabinogalacto-oligosaccharides, gluco-oligosaccharides, gentio-oligosaccharides, glucomanno-oligosaccharides, galactomannooligosaccharides, mannan-oligosaccharides, isomalto-oligosaccharides, nigero-oligosaccharides, glucomanno-oligosaccharides, chito-oligosaccharides, soy oligosaccharides, uronic acid oligosaccharides, N-acetylated oligosaccharides, fuco-oligosaccharides, and sialylyoligosaccharides. Such oligosaccharides share many biochemical properties and have similar functional benefits including improving the intestinal microbiota-function. Yet is understood that some non-digestible oligosaccharides and preferably some mixtures have an even further improved effect. T

[0109] Herefore, more preferably the non-digestible oligosaccharides are selected from the group consisting of fructo-oligosaccharides, such as inulin, and galacto-oligosaccharides, such as betagalactooligosaccharides, and mixtures thereof, even more preferably beta-galacto-oligosaccharides and / or inulin, most preferably beta-galacto-oligosaccharides.

[0110] Preferably the non-digestible oligosaccharides comprise galacto-oligosaccharides with beta(1 ,4), beta(1 ,3) and / or beta(1 ,6) glycosidic bonds and a terminal glucose. Transgalacto-oligosaccharides is for example available under the trade name VivinalOGOS (Domo FrieslandCampina Ingredients), Bi2muno (Clasado), Cup-oligo (Nissin Sugar) and Oligomate55 (Yakult).

[0111] The non-digestible oligosaccharides preferably comprise fructo-oligosaccharides. Fructooligosaccharides may in other context have names like fructopolysaccharides, oligofructose, short chain fructooligosaccharide, long chain fructooligosaccharide, polyfructose, polyfructan, inulin, levan and fructan and may refer to oligosaccharides comprising beta-linked fructose units, which are preferably linked by beta(2,1) and / or beta(2,6) glycosidic linkages, and a preferable DP between 2 and 200. Preferably, the fructo-oligosaccharides contain a terminal beta(2,1) glycosidic linked glucose. Preferably, the fructo-oligosaccharides contain at least 7 beta-linked fructose units. In a further preferred embodiment inulin is used. Inulin is a type of fructo-oligosaccharides wherein at least 75% of the glycosidic linkages are beta(2,1) linkages. Typically, inulin has an average chain length between 8 and 60 monosaccharide units. A suitable fructo-oligosaccharides for use in the compositions of the present invention is commercially available under the trade name RaftilineOHP (Orafti). Other suitable sources are Raftilose (Orafti), Fibrulose and Fibruline (Cosucra) and Frutafit and Frutalose (Sensus).

[0112] Preferably the present nutritional composition comprises a mixture of galacto-oligosaccharides and fructo-oligosaccharides. Preferably the mixture of galacto-oligosaccharides and fructo-oligosaccharides is present in a weight ratio of from 1 / 99 to 99 / 1 , more preferably from 1 / 19 to 19 / 1 , more preferably from 1 / 1 to 19 / 1 , more preferably from 2 / 1 to 15 / 1 , more preferably from 5 / 1 to 12 / 1 , even more preferably from 8 / 1 to 10 / 1 , even more preferably in a ratio of about 9 / 1. This weight ratio is particularly advantageous when the galacto-oligosaccharides have a low average DP and fructo-oligosaccharides has a relatively high DP. Most preferred is a mixture of galacto-oligosaccharides with an average DP below 10, preferably below 6, and fructo-oligosaccharides with an average DP above 7, preferably above 20. The present nutritional composition preferably comprises 2.5 to 20 wt% total non-digestible oligosaccharides, more preferably 2.5 to 15 wt%, even more preferably 3.0 to 10 wt%, most preferably 5.0 to 7.5 wt%, based on dry weight of the nutritional composition. Based on 100 ml the present nutritional composition preferably comprises 0.35 to 2.5 wt% total non-digestible oligosaccharides, more preferably 0.35 to 2.0 wt%, even more preferably 0.4 to 1.5 wt%, based on 100 ml of the nutritional composition. A lower amount of non-digestible oligosaccharides will be less effective in stimulating bifidobacterial thereby increasing ILA and IML production, whereas a too high amount will result in sideeffects of bloating and abdominal discomfort.

[0113] LC-PUFA

[0114] Preferably the nutritional composition comprises long chain poly-unsaturated fatty acids (LC-PUFA). CYCP1A1 , induced by AhR, is known to be able to metabolize LC-PUFA like Arachidonic acid (ARA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) to metabolites that have a positive effect on hypertension and inflammation.

[0115] LC-PUFA are fatty acids or fatty acyl chains with a length of 20 to 24 carbon atoms, preferably 20 or 22 carbon atoms, comprising two or more unsaturated bonds. Preferably the composition comprises at least one, preferably two, more preferably three LC-PUFA selected from docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and arachidonic acid (ARA). Preferably, the sum of DHA, ARA and EPA is of 0.4 to 5.0 wt% based on total fatty acids. This is considered most optimal range to be used in infant formula.

[0116] Preferably the amount of DHA is at least 0.4 wt%, preferably at least 0.5 wt% based on total fatty acids. Preferably the amount of DHA is not more than 1 wt% based on total fatty acids. Preferably the nutritional composition comprises an amount of EPA of at least 0.09 wt%, preferably at least 0.1 wt%, based on total fatty acids, and preferably not more than 0.4 wt%. Preferably the nutritional composition comprises an amount of ARA of at least 0.25 wt% based on total fatty acids, more preferably at least 0.5 wt% and preferably not more than 1 wt%. It is particularly preferred that the nutritional composition comprises DHA in amount of more than 0.5 wt% based on total fatty acids, and EPA in an amount of more than 0.1 wt% based on total fatty acids. Preferably the nutritional composition comprises DHA, EPA, and ARA in amount of 0.4 to 1 .0 wt%, of 0.09 to 0.4 wt%, and of 0.25 to 1 .0 wt % based on total fatty acids, respectively. More preferably the nutritional composition comprises DHA, EPA, and ARA in amount of 0.5 to 0.7 wt%, of 0.1 to 0.2 wt%, and of 0.5 to 0.7 wt % based on total fatty acids, respectively.

[0117] Preferably the nutritional composition comprises DHA in amount of 20 to 50 mg / 100 kcal and EPA in an amount of 4.3 to 10.8 mg / 100 kcal. More preferably the nutritional composition comprises DHA in an amount of 25 to 33.5 mg / 100 kcal and EPA in an amount of 5.4 to 7.2 mg / 100 kcal. Most preferably the nutritional composition comprises DHA in amount of about 25 mg / 100 kcal and EPA in an amount of about 5.4 mg / 100 kcal. In these embodiments the presence of ARA is optional. If present, the amount of ARA is preferably 12.5 to 50 mg, more preferably 25 to 33.5 mg and most preferably about 25 mg per 100 kcal. Preferably the weight ratio of DHA / ARA is from 0.9 to 2. The LC-PUFA may be provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, or as a mixture of one of more of the above. Suitable sources of these LC-PUFA are e.g., fish oil, algal oil and oil from Mortierella alpina.

[0118] In an embodiment, the nutritional composition according to the present invention thus comprises lipid, wherein the lipid comprises LC-PUFA selected from the group consisting of DHA, EPA, and ARA, and wherein the sum of DHA, ARA and EPA is at least 1 wt% based on total fatty acids. In another embodiment, the lipid comprises at least 0.1 wt% EPA acid based on total fatty acids and at least 0.5 wt % DHA based on total fatty acids, and optionally further at least 0.25 wt% ARA based on total fatty acids. More preferably the lipid comprises at least 0.1 wt% EPA, at least 0.5 wt % DHA and at least 0.25 wt% ARA, all based on total fatty acids. Even more preferably the lipid comprises LC-PUFA selected from the group consisting of DHA, EPA and ARA, wherein the sum of DHA, ARA and EPA is at least 1 wt% based on total fatty acids, and wherein the lipid comprises at least 0.1 wt% EPA, at least 0.5 wt % DHA and at least 0.5 wt% ARA, all based on total fatty acids.

[0119] Preferably the nutritional composition according to the present invention comprises lipid, wherein the lipid comprise LC-PUFA selected from the group consisting of DHA, EPA and ARA, and wherein the sum of DHA, ARA and EPA is at least 1 wt% based on total fatty acids, and wherein the lipid comprises DHA in amount of 0.4 to 1 .0 wt% based on total fatty acids, EPA in an amount of 0.09 to 0.4 wt% based on total fatty acids and ARA in an amount of 0.25 to 1 wt% based on total fatty acids. In this embodiment it is further preferred that the lipid comprises DHA in an amount of 0.5 to 0.7 wt% based on total fatty acids, EPA in an amount of 0.1 to 0.2 wt% based on total fatty acids and ARA in an amount of 0.5 to 0.7 wt% based on total fatty acids. More preferably the lipid comprises DHA in an amount of at least 0.5 wt%, EPA in an amount of at least 0.1 wt% wt% and ARA in an amount of at least 0.5 wt%, all based on total fatty acids.

[0120] Nutritional composition

[0121] The nutritional composition used according to the present invention is preferably for enteral administration, more preferably for oral administration. The present nutritional composition is not human or mammalian milk. The nutritional composition is a synthetic nutritional composition.

[0122] The present nutritional composition is preferably an infant formula, follow on formula, toddler milk or toddler formula, or growing up milk intended for young children. More preferably the nutritional composition is an infant formula or follow on formula. The present nutritional composition can be advantageously applied as a complete nutrition for infants. Preferably the present nutritional composition is an infant formula. An infant formula is defined as a formula for use in infants and can for example be a starter formula, intended for infants of 0 to 6 or 0 to 4 months of age. A follow-on formula is intended for infants of 4 or 6 months to 12 months of age. At this age infants start weaning on other food. A toddler or growing up milk or formula is intended for children of 1 to 3 years of age. The present composition preferably comprises a lipid component, protein component and carbohydrate component and is preferably administered in liquid form. The present nutritional composition may also be in the form of a dry food, preferably in the form of a powder which is accompanied with instructions as to mix said dry food, preferably powder, with a suitable liquid, preferably water. The nutritional composition used according to the invention preferably comprises other fractions, such as vitamins, minerals, trace elements and other micronutrients in order to make it a complete nutritional composition. Preferably infant formulas comprise vitamins, minerals, trace elements and other micronutrients according to international directives.

[0123] The present nutritional composition preferably comprises lipid, protein, and digestible carbohydrate wherein the lipid provides 5 to 50% of the total calories, the protein provides 5 to 50% of the total calories, and the digestible carbohydrate provides 15 to 90% of the total calories. Preferably, in the present nutritional composition the lipid provides 35 to 50% of the total calories, the protein provides 7.0 to 12.5% of the total calories, and the digestible carbohydrate provides 40 to 55% of the total calories. For calculation of the % of total calories for the protein, the total of energy provided by proteins, peptides and amino acids needs to be taken into account. Preferably the lipid provides 3 to 7 g lipid per 100 kcal, preferably 4 to 6 g per 100 kcal, the protein provides 1 .6 to 4 g per 100 kcal, preferably 1 .7 to 2.5 g per 100 kcal and the digestible carbohydrate provides 5 to 20 g per 100 kcal, preferably 8 to 15 g per 100 kcal of the nutritional composition. Preferably the present nutritional composition comprises lipid providing 4 to 6 g per 100 kcal, protein providing 1 .6 to 2.0 g per 100 kcal, more preferably 1 .7 to 1 .9 g per 100 kcal and digestible carbohydrate providing 8 to 15 g per 100 kcal of the nutritional composition. In one embodiment, the lipid provides 3 to 7 g lipid per 100 kcal, preferably 4 to 6 g per 100 kcal, the protein provides 1.6 to 2.1 g per 100 kcal, preferably 1.6 to 2.0 g per 100 kcal and the digestible carbohydrate provides 5 to 20 g per 100 kcal, preferably 8 to 15 g per 100 kcal of the nutritional composition and wherein preferably the digestible carbohydrate component comprises at least 60 wt% lactose based on total digestible carbohydrate, more preferably at least 75 wt%, even more preferably at least 90 wt% lactose based on total digestible carbohydrate. The amount of total calories is determined by the sum of calories derived from protein, lipids, digestible carbohydrates and non- digestible oligosaccharide.

[0124] The present nutritional composition preferably comprises a digestible carbohydrate component. Preferred digestible carbohydrate components are lactose, glucose, sucrose, fructose, galactose, maltose, starch and maltodextrin. Lactose is the main digestible carbohydrate present in human milk. The present nutritional composition preferably comprises lactose. As the present nutritional composition comprises a fermented composition that is obtained by fermentation by lactic acid producing bacteria, the amount of lactose is reduced compared to its source due to the fermentation whereby lactose is converted into lactate and / or lactic acid. Therefore, in the preparation of the present nutritional composition lactose is preferably added. Preferably the present nutritional composition does not comprise high amounts of carbohydrates otherthan lactose. Compared to digestible carbohydrates such as maltodextrin, sucrose, glucose, maltose and other digestible carbohydrates with a high glycemic index, lactose has a lower glycemic index and is therefore preferred. The present nutritional composition preferably comprises digestible carbohydrate, wherein at least 35 wt%, more preferably at least 50 wt%, more preferably at least 60 wt%, more preferably at least 75 wt%, even more preferably at least 90 wt%, most preferably at least 95 wt% of the digestible carbohydrate is lactose. Based on dry weight the present nutritional composition preferably comprises at least 25 wt% lactose, preferably at least 40 wt%, more preferably at least 50 wt% lactose.

[0125] The present nutritional composition preferably comprises at least one lipid selected from the group consisting of animal lipid (excluding human lipids) and vegetable lipids. Preferably the present composition comprises a combination of vegetable lipids and at least one oil selected from the group consisting of fish oil, animal oil, algae oil, fungal oil, and bacterial oil. The lipid of the present nutritional composition preferably provides 3 to 7 g per 100 kcal of the nutritional composition, preferably the lipid provides 4 to 6 g per 100 kcal. When in liquid form, e.g., as a ready-to-feed liquid, the nutritional composition preferably comprises 2.1 to 6.5 g lipid per 100 ml, more preferably 3.0 to 4.0 g per 100 ml. Based on dry weight the present nutritional composition preferably comprises 12.5 to 40 wt% lipid, more preferably 19 to 30 wt %.

[0126] The present nutritional composition preferably comprises protein. The protein used in the nutritional composition is preferably selected from the group consisting of non-human animal proteins, preferably milk proteins, vegetable proteins, such as preferably soy protein and / or rice protein, and mixtures thereof. The present nutritional composition preferably contains casein, and / or whey protein, more preferably bovine whey proteins and / or bovine casein. Thus, in one embodiment the protein in the present nutritional composition comprises protein selected from the group consisting of whey protein and casein, preferably whey protein and casein, preferably the whey protein and / or casein is from cow’s milk. Preferably the protein comprises less than 5 wt% based on total protein of free amino acids, dipeptides, tripeptides or hydrolysed protein. The present nutritional composition preferably comprises casein and whey proteins in a weight ratio casein : whey protein of 10 : 90 to 90 : 10, more preferably 20 : 80 to 80 : 20, even more preferably 35 : 65 to 55 : 45. The protein contains histidine and tryptophan.

[0127] The wt% protein based on dry weight of the present nutritional composition is calculated according to the Kjeldahl-method by measuring total nitrogen and using a conversion factor of 6.38 in case of casein, or a conversion factor of 6.25 for other proteins than casein. The term ‘protein’ or ‘protein component’ as used in the present invention refers to the sum of proteins, peptides and free amino acids.

[0128] The present nutritional composition preferably comprises protein providing 1 .6 to 4.0 g protein per 100 kcal of the nutritional composition, preferably providing 1 .6 to 3.5 g, even more preferably 1 .75 to 2.5 g per 100 kcal of the nutritional composition. In one embodiment, the present nutritional composition comprises protein providing 1.6 to 2.1 g protein per 100 kcal of the nutritional composition, preferably providing 1 .6 to 2.0 g, more preferably 1 .7 to 2.1 g, even more preferably 1 .75 to 2.0 g per 100 kcal of the nutritional composition. In one embodiment, the present nutritional composition comprises protein in an amount of less than 2.0 g per 100 kcal, preferably providing 1.6 to 1.9 g, even more preferably 1.75 to 1.85 g per 100 kcal of the nutritional composition. A too low protein content based on total calories will result is less adequate growth and development in infants and young children. A too high amount will put a metabolic burden, e.g., on the kidneys of infants and young children. When in liquid form, e.g. as a ready-to-feed liquid, the nutritional composition preferably comprises 0.5 to 6.0 g, more preferably 1 .0 to 3.0 g, even more preferably 1 .0 to 1 .5 g protein per 100 ml, most preferably 1 .0 to 1 .3 g protein per 100 ml. Based on dry weight the present nutritional composition preferably comprises 5 to 20 wt% protein, preferably at least 8 wt% protein based on dry weight of the total nutritional composition, more preferably 8 to 14 wt%, even more preferably 8 to 9.5 wt% protein based on dry weight of the total nutritional composition.

[0129] In order to meet the caloric requirements of an infant or toddler, the nutritional composition preferably comprises 45 to 200 kcal / 100 ml liquid. For infants the nutritional composition has more preferably 60 to 90 kcal / 100 ml liquid, even more preferably 65 to 75 kcal / 100 ml liquid. This caloric density ensures an optimal ratio between water and calorie consumption. For toddlers, human subjects with an age between 12 and 36 months, the nutritional composition more preferably has a caloric density between 45 and 65, even more preferably between 50 and 60 kcal / 100 ml. The osmolarity of the present composition is preferably between 150 and 420 mOsmol / l, more preferably 260 to 320 mOsmol / l.

[0130] When the nutritional composition is in a ready to feed, liquid form, the preferred volume administered on a daily basis is in the range of about 80 to 2500 ml, more preferably about 200 to 1200 ml per day. Preferably, the number of feedings per day is between 1 and 10, preferably between 3 and 8. In one embodiment the nutritional composition is administered daily for a period of at least 2 days, preferably for a period of at least 4 weeks, preferably for a period of at least 8 weeks, more preferably for a period of at least 12 weeks, in a liquid form wherein the total volume administered daily is between 200 ml and 1200 ml and wherein the number of feedings per day is between 1 and 10.

[0131] The present nutritional composition, when in liquid form, preferably has a viscosity between 1 and 60 mPa.s, preferably between 1 and 20 mPa.s, more preferably between 1 and 10 mPa.s, most preferably between 1 and 6 mPa.s. The low viscosity ensures a proper administration of the liquid, e.g., a proper passage through the whole of a nipple. Also, this viscosity closely resembles the viscosity of human milk. Furthermore, a low viscosity results in a normal gastric emptying and a better energy intake, which is essential for infants which need the energy for optimal growth and development. The present nutritional composition alternatively is in powder form, suitable for reconstitution with water to a ready to drink liquid. The present nutritional composition is preferably prepared by admixing a powdered composition with water. Normally infant formula is prepared in such a way. The present invention thus also relates to a packaged power composition wherein said package is provided with instructions to admix the powder with a suitable amount of liquid, thereby resulting in a liquid composition with a viscosity between 1 and 60 mPa.s. The viscosity of the liquid is determined using a Physica Rheometer MCR 300 (Physica Messtechnik GmbH, Ostfilden, Germany) at a shear rate of 95 s-1at 20 °C. A suitable equipment to measure the viscosity is Physica Rheometer MCR 300 (Physica Messtechnik GmbH, Ostfilden, Germany). AhR and CYP1A1

[0132] The inventors found that a combination of ILA and IML synergistically activated AhR and induced CYP1A1. While ILA is known as AhR ligand, IML has not been described as AhR activator before. It was indeed found that IML alone could not activate AhR, yet in combination with ILA activated AhR in a more than additive, i.e., synergistic, manner. AhR has been implicated in numerous physiological and immunological processes. The receptor is in addition typically known for regulating expression of the cytochrome P450 family hydroxylases, such as CYP1A1 and CYP1 B1 active in the xenobiotic metabolism of polycyclic aromatic hydrocarbons and polyunsaturated fatty acids.

[0133] CYP1A1 is involved in phase 1 xenobiotic and drug metabolism. CYP1A1 is also known as aryl hydrocarbon hydroxylase (AHH) and is highly active in the intestinal mucosa, and thus inhibits infiltration of ingested detrimental xenobiotic aromatic hydrocarbons like drugs, pesticides, and pollutants into the systemic circulation by metabolizing it into less harmful compounds. However, it’s been shown that CYP1A1 also metabolizes endogenous compounds and plays a role in maintaining gut homeostasis. Bilirubin can activate CYP1A1 via AhR (De Matteis, Dawson et al. 1991 , Sinai and Bend 1997), which contributes to its hydroxylation and hence detoxification. So, the activation of CYP1A1 by other means, e.g., bacterial metabolites might help to reduce bilirubin levels in infants to prevent and / ortreat jaundice. Infants, especially pre-term babies, might have problems breaking down bilirubin, leading to jaundice. Untreated high levels of bilirubin in infants can further cause kernicterus, a condition linked with athetoid cerebral palsy, hearing loss, vision impairments and intellectual disabilities. The combination of ILA and IML therefore, via its beneficial increase in detoxification capacity, AhR activation and CYP1A1 expression induction, improves and / or treats and / or reduces bilirubin levels in infants.

[0134] CYP1A1 also metabolizes polyunsaturated fatty acids [PUFA] into signaling molecules. It metabolizes arachidonic acid [ARA] to 19-hydroxyeicosatetraenoic acid (19-HETE) and docosahexaenoic acid [DHA] to primarily 19R,20S-epoxyeicosapentaenoic acid and 19S,20R-epoxyeicosapentaenoic acid isomers (termed 19,20-EDP) and metabolizes eicosapentaenoic acid [EPA] to epoxides, primarily 17R.18S- eicosatetraenoic acid and 17S,18R-eicosatetraenoic acid isomers (termed 17,18-EEQ). 19-HETE is an inhibitor of 20-HETE and thereby may have a positive effect on preventing elevated blood pressure and promoting inflammation responses. The EDP and EEQ metabolites decrease hypertension and pain perception and suppress inflammation. In an aspect of the invention ILA and IML are thus beneficial for use in treating elevated blood pressure and / or hypertension.

[0135] Application

[0136] The methods, composition, and combination for use according to the present invention comprising administering the present nutritional composition also refer to administering an effective amount of the nutritional composition to the subject in need thereof. The present nutritional composition comprising ILA and IML is preferably administered to an infant or young child. Infants are defined as a human subject with an age of 0 to 12 months. Young children have an age of 1 to 3 years.

[0137] In a preferred embodiment, the methods or uses according to the present invention are for healthy infants, term infants, preterm infants, low birth weight infants, C-section born infants and antibiotic treated infants.

[0138] In a preferred aspect the invention concerns the non-therapeutic method comprising administering a combination of indole lactic acid (ILA) and imidazole lactic acid (IML) for improving the detoxification capacity in human subjects, preferably healthy infants and / or term infants. Improving detoxification capacity in said method preferably involves increasing AhR activity and / or increasing expression of CYP1A1.

[0139] In a further preferred aspect, the invention concerns therapeutic uses wherein the infant is preterm or has very low birth weight. Preferably the infant is 0 to 12 months, more preferably 0 to 4 months of age. In a preferred further aspect, the infants are those that are more vulnerable to exposure to harmful substances and / or have an intestinal microbiota that is low in bifidobacterial, such as preterm infants, low birth weight (LBW) infants, very low birth weight (VLBW) infants, C-section born infants and / or antibiotic treated infants. Such infants with low intestinal bifidobacterial may produce less endogenous IML and ILA and may especially benefit from administering a nutritional composition comprising ILA and IML. Therapeutic aspects and applications involve mitigating harmful effects caused by toxins, in particular aromatic hydrocarbons in a human subject, improving or increasing detoxification capacity in a human by activating the AhR, improving or increasing detoxification capacity in a human subject by increasing CYP1A1 expression and / or improving bilirubinemia.

[0140] Infants, especially preterm or LBW infants, might have problems breaking down bilirubin, leading to hyperbilirubinemia and jaundice. Untreated high levels of bilirubin in infants can further cause kernicterus, a condition linked with athetoid cerebral palsy, hearing loss, vision impairments and intellectual disabilities. Such infants could especially benefit from improved detoxification of bilirubin and benefit from administering a nutritional composition comprising ILA and IML.

[0141] In a further preferred aspect, the invention concerns therapeutic uses comprising a combination of ILA and IML or nutritional compositions comprising a combination of ILA and IML for use in treating and / or preventing elevated blood pressure and / or hypertension, preferably in an adult subject. Treating and / or preventing elevated blood pressure and / or hypertension involves activating AhR. EXAMPLES

[0142] Example 1: ILA and IML levels in postbiotic IFFO, standard IFFO, and human milk

[0143] ILA and IML levels were assessed in different infant nutrition samples. The assessed samples were as follows:

[0144] 1. Standard non fermented infant formula with whey protein and casein 6:4 with GOS-FOS (formula 1);

[0145] 2. Infant formula with 26% fermented fraction, comprising whey protein and casein 5:5 with GOS- FOS (Aptamil Profutura duobiotic) (formula 2);

[0146] 3. The 100% fermented basepowder (Lactofidus) that was used for formula 2. The fermentation process is as described above (100% fermented formula).

[0147] In addition, human milk was tested.

[0148] Samples were sent to the commercial laboratory Metabolon (Durham, NC) for metabolite detection. Procedures for this metabolic profiling have been described previously (Chow J et al J Proteome Res, 2014). In short, samples were extracted and split into equal parts for analysis on for the four technical platforms from which the results are used in combination. The used platforms were GC-MS, polar LC, LC-MS / MS optimized for positive ionization, and LC-MS / MS optimized for negative ionization. Proprietary software was used to match detected ion peaks to an in-house library of standards (Metabolon, Durham, NC) for metabolite identification. Quantitation was done by using the area-under- the-curve approach on the ion peaks. Data were collected over multiple platform-run-days and were adjusted by scaling to the median values for each group-balanced run-day block for each individual compound. This approach minimizes any inter-day instrument gain or drift but does not interfere with intraday sample variability. Data were not otherwise adjusted or normalized.

[0149] The presence of the metabolites ILA and IML was detected in formula that was partly fermented (formula 2) using an untargeted metabolomics approach. The signals for ILA (figure 1A) were increased compared to regular formula (formula 1).

[0150] The signals for IML (figure 1 B) were found to be increased for the formula that is partly fermented (formula 2). Non-fermented formulas, both with and without GOS / FOS did not show ILA and IML levels above detection level (formula 1 and data not shown). The amounts of ILA and IML in human milk were below detection level for ILA, and at a median signal intensity of 526957 for IML.

[0151] Example 2: Activation ofAhR by ILA is enhanced in the presence of IML.

[0152] The capacity of ILA, IML and mixtures thereof were assessed in their potential to activate AhR. Treatment sample preparation for AhR reporter assay: Lyophilized metabolites indole lactic acid (ILA) (Sigma-Aldrich, Cat No. I5508) and imidazole lactic acid (IML) (MolPort, Cat No. 046-589-611) were reconstituted in dimethyl sulfoxide (Sigma-Aldrich, Cat No. D4540) to obtain high-concentrated stock solutions of 1 M. Treatment samples were prepared by further diluting ILA and IML stock solutions to the desired final concentrations using the Compound Screening Media (CSM) included in the AhR reporter kit. AhR reporter assay experiments: The activation of the aryl hydrocarbon receptor was followed using an AhR-reporter assay (Indigo Bioscience, Cat No. IB06001-32) following the manufacturer’s protocol. In brief, modified human Huh7 cells were reconstituted in recovery media, dispensed into white-bottom 96- well plates and incubated for 4-6 hours at 37°C and 5% CO2. Following the pre-incubation period, the recovery medium was discarded and 200 pl of the treatment samples of interest were added to the cells. All samples were assessed in triplo. The plate was then returned to the incubator for a period of 24 hours. After the 24-hour incubation time, treatment samples were removed and 100 pl of the luciferase detection reagent were dispensed in each well. Lastly, luciferase activity was measured in a plate reader at a reading time of 0.5 seconds per well and expressed in relative light units (RLU).

[0153] Statistics: To conduct statistical analysis, the relative light units derived from the samples under study were normalized to an equivalent concentration of a reference agonist, MeBio, which was part of the kit. To achieve this, a set of known MeBio concentrations was included in all three biological replicates. The resulting RLU’s measured for the MeBio series were used as a standard curve to interpolate the equivalent concentrations of the treatments of interest. Finally, statistical analyses were conducted on these values, and significant differences were identified using One-way ANOVA, followed by Tukey’s multiple comparison test. Mean AhR activation by 1 mM ILA, 1 mM IML, the combination thereof as well as the expected calculated AhR activitation of the combination are shown in figure 2.

[0154] Figure 2 shows AhR activation by the treatments of interest: ILA 1 mM, IML 1 mM and the combination ILA 1 mM + IML 1 mM. Activation of the AhR was determined by the quantification of luciferase activity. Relative light units were then normalized to a reference agonist MeBio. The “theoretical” treatment condition corresponds to the theoretical response based on the addition of the individual responses elicited by ILA and IML.

[0155] Results: It was found that ILA activated the AhR activity, whereas IML did not. Surprisingly the activation of AhR with the combination of ILA and IML resulted in a statistically significant higher activation than expected based on the effect observed with the single treatment conditions.

[0156] Example 3: CYP1A1 induction by ILA is increased in the presence of IML

[0157] Next the expression induction of CYP1A1 by ILA and IML was assessed in vitro.

[0158] Cell culture: HT-29 cells were maintained in RPMI 1640 medium (Thermofisher, Cat No. 11875093) supplemented with 10% FCS that was heat inactivated (Gibco, 10270-106), 100 lU / ml penicillin and 100 pg / ml streptomycin (Gibco, Cat No. 15140122), at 37°C and 5% CO2. The cells were used for experiments at passage number 153. Cells’ medium was refreshed every other day and the culture was split every 3 to 4 days. For CYP1 A1 expression experiments, HT-29 cells were trypsinized and seeded at a density of 100.000 cells per well in 24-well plates (Corning, Cat No. 3524). Cells were grown for 3 days in complete medium and on the day of the experiment, the culture medium was removed and replaced for RPMI 1640 serum free.

[0159] Treatment preparation for CYP1A1 expression: Lyophilized metabolites indole lactic acid (ILA) (Sigma- Aldrich, Cat No. I5508) and imidazole lactic acid (IML) (MolPort, Cat No. 046-589-611) were 1 reconstituted in dimethyl sulfoxide (Sigma-Aldrich, Cat No. D4540) to obtain high-concentrated stock solutions of 1 M. Treatments were prepared by further diluting ILA and IML stock solutions to the desired final concentrations using the treatment media RPMI serum free. One milliliter of treatment medium was dispensed into the HT-29 cells and the plate was incubated at 37°C and 5% CO2 for four days. Medium was refreshed at day 2 and RNA samples were collected at day 0 and day 4.

[0160] Gene expression experiments: Total RNA was isolated from HT-29 cells using Qiagen’s RNeasy Plus Mini kit (Qiagen, Cat No. 74034) and stored at -80C in RNase-free water until required. Complementary DNA was synthesized from 1 pg of extracted RNA using the BIO-RAD iScript cDNA synthesis kit (BIORAD, Cat No. 1708891). Quantitative real-time PCR was performed using the following primers: Cytochrome P450 Family 1 Subfamily A Member 1 (CYP1A1): forward primer 5- ACATGCTGACCCTGGGAAAG 3- (SEQ ID 1), reverse primer 5- GGTGTGGAGCCAATTCGGAT 3- (SEQ ID 2); and Cyclophilin a (CyPA): forward primer 5- CGGGTCCTGGCATCTTGTCC 3- (SEQ ID 3), reverse primer 5- GCCAAACACCACATGCTTGCC 3- (SEQ ID 4). The relative fold gene expression of the gene of interest was normalized to the expression of the housekeeping gene cyclophilin a by the 2- AACt method (table 2).

[0161] Table 1. CYP1A1 relative expression (x 104) normalized to the expression of the housekeeping gene cyclophilin a by the 2-AACt method and not corrected for the background of the cell medium control.

[0162] Relative fold gene expression of CYP1A1 was normalized to the expression of the housekeeping gene cyclophilin a by the 2-AACt method. ILA resulted in increased expression of the CYP1 A1 , whereas IML alone had no effect on CYP1A1 expression. Surprisingly in the presence of both ILA and IML the expression of CYP1A1 was more than twice as high as expected based on the single ingredients.

[0163] Example 4: Nutritional composition

[0164] An exemplary cow’s milk based nutritional composition is provided.

[0165] An infant formula is provided as a powder in a pack with instructions to reconstitute with water to a ready to drink milk. The infant formula contains a fermented formula in a proportion of 30 wt% of the total composition based on dry weight. The fermented formula fraction underwent a fermentation process (Lactofidus™) with two bacterial strains Bifidobacterium breve C50 (CNCM 1-2219) and Streptococcus thermophilus 065 (CNCM 1-1620) wherein the bacteria were heat-inactivated after fermentation. The infant formula comprised about 0.33 wt% of the sum of lactic acid and lactate based on dry weight of the composition, of which at least 95 wt% was L-lactic acid + L-lactate. When reconstituted the formula contains per 100 ml: 68 kcal

[0166] 3 mg ILA

[0167] 3 mg IML about 1 .4 g protein (mainly whey protein and casein from bovine) [casein / whey protein 1 :1] - about 3.2 g lipid, wherein the amount of DHA is 0.52 wt%, EPA is 0.11 wt% and ARA is 0.52 wt% based on total fatty acids about 8.1 g digestible carbohydrates (mainly lactose) about 815 mg non-digestible oligosaccharides, comprising about 745 mg galactooligosaccharides ( Vivinal GOS and 15 mg 3’galactosyllactose from the fermentation) and about 80 mg IcFOS (source RaftilinHP) minerals, trace elements, vitamins and other micronutrients as known in the art and according to international directives for infant formula.

[0168] (Original in Electronic Form)

[0169] (This sheet is not part of and does not count as a sheet of the international application)

[0170] FOR RECEIVING OFFICE USE ONLY

[0171] FOR INTERNATIONAL BUREAU USE ONLY

Claims

29CLAIMS:

1. A non-therapeutic method for increasing and / or improving detoxification capacity in a human subject comprising administering a combination of indole lactic acid (ILA) and imidazole lactic acid (IML).

2. The non-therapeutic method according to claim 1 wherein increasing and / or improving detoxification capacity in a human subject involves increasing AhR activity and / or increasing expression of CYP1 A1 .

3. The non-therapeutic method according to claims 1 and 2 wherein the combination of ILA and IML is comprised in a nutritional composition.

4. The non-therapeutic method according to claim 3 wherein the nutritional composition comprises lactic acid producing bacteria, preferably selected from the group consisting of Bifidobacterium and Streptococcus, more preferably S. thermophilus, B. breve, B. longum spp longum, B. bifidum and / or B. longum spp infantis, most preferably B. breve.

5. The non-therapeutic method according to claim 3 or 4 wherein the nutritional composition is at least partly fermented by lactic acid producing bacteria, preferably comprising 0.1 to 1.5 wt percent of the sum of lactic acid and lactate based on dry weight of the composition.

6. The non-therapeutic method according to claims 3 to 5 wherein the nutritional composition comprises 2.5 to 15 wt percent non-digestible oligosaccharides based on dry weight of the nutritional composition and the non-digestible oligosaccharides are selected from the group consisting of fructo-oligosaccharides, non-digestible dextrins, galacto-oligosaccharides, xylooligosaccharides, arabino-oligosaccharides, arabinogalacto- oligosaccharides, glucooligosaccharides, gentio-oligosaccharides, glucomanno-oligosaccharides, galactomannooligosaccharides, mannan-oligosaccharides, isomalto-oligosaccharides, nigero-oligosaccharides, chito-oligosaccharides, soy oligosaccharides, uronic acid oligosaccharides, N-acetylated oligosaccharides, sialyl-oligosaccharides and fuco- oligosaccharides, and mixtures thereof, preferably galacto-oligosaccharides and fructo-oligosaccharides and / or wherein the nutritional composition comprises at least one long chain poly-unsaturated fatty acid [LC-PUFA], preferably at least two LC-PUFAs, selected from the group consisting of DHA, EPA and ARA.

7. The non-therapeutic method according to claims 3 to 6 wherein the combination of ILA and IML is comprised in a nutritional composition and the nutritional composition is an infant formula or a follow-on formula.

8. The non-therapeutic method according to the preceding claims wherein the human subject is a healthy, term infant or young child.

309. The non-therapeutic method according to the preceding claims wherein detoxification capacity is increased and / or improved compared to human subjects not being administered a combination of ILA and IML and / or wherein increasing and / or improving detoxification capacity occurs in the gastrointestinal tract of said human subject.

10. A nutritional composition comprising a combination of indole lactic acid (ILA) and imidazole lactic acid (IML) for use in a. mitigating harmful effects caused by toxins, in particular aromatic hydrocarbons in a human subject; b. increasing and / or improving or increasing detoxification capacity in a human by activating the AhR; c. increasing and / or improving detoxification capacity in a human subject by increasing CYP1A1 expression; d. improving bilirubinemia compared to a human subject being administered a nutritional composition that does not comprise ILA and IML.

11. The nutritional composition for use according to claim 10 wherein the nutritional composition comprises lactic acid producing bacteria, preferably selected from the group consisting of Bifidobacterium and Streptococcus, more preferably S. thermophilus, B. breve, B. longum spp longum, B. bifidum and / or B. longum spp infantis, most preferably B. breve.

12. The nutritional composition for use according to claims 10 to 11 wherein the nutritional composition is at least partly fermented by lactic acid producing bacteria, preferably comprising 0.1 to 1.5 wt percent of the sum of lactic acid and lactate based on dry weight of the composition and / or preferably comprising tryptophan and histidine.

13. The nutritional composition for use according to claim 12, wherein the nutritional composition comprises tryptophan and histidine and is at least partially fermented by Bifidobacterium and optionally by Streptococcus thermophilus, preferably a Bifidobacterium selected from B. breve, B. longum spp infantis, B. bifidum and B. longum spp infantis, most preferably B. breve and wherein preferably the lactic acid producing bacteria are inactivated after fermentation.

14. The nutritional composition for use according to claims 10 - 13 wherein the composition further comprises non-digestible oligosaccharides selected from the group consisting of fructooligosaccharides, non-digestible dextrins, galacto-oligosaccharides, xylo-oligosaccharides, arabino-oligosaccharides, arabinogalacto-oligosaccharides, gluco-oligosaccharides, gentio- oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, mannan-oligosaccharides, isomalto-oligosaccharides, nigero-oligosaccharides, chito-oligosaccharides, soy oligosaccharides, uronic acid oligosaccharides, N-acetylated oligosaccharides, sialyloligosaccharides and fuco-oligosaccharides, and mixtures thereof preferably the non- digestible oligosaccharide are GOS and / or FOS.

15. The nutritional composition for use according to claims 10 to 14 wherein the nutritional composition comprises at least one long chain poly-unsaturated fatty acid [LC-PUFA], preferably at least two LC-PUFAs, selected from the group consisting of DHA, EPA, and ARA.

16. The nutritional composition for use according to claims 10 to 15, wherein improving and / or increasing detoxification capacity involves AhR activation and / or CYP1A1 expression induction and wherein improving and / or increasing detoxification capacity occurs in the gastrointestinal tract of said human.

17. The nutritional composition for use according to claims 10 to 16, wherein the nutritional composition is selected from an infant formula and a follow-on formula and wherein the composition is administered to an infant or young child, preferably an infant, more preferably to a preterm infant, C-section born infant or an infant that received antibiotics.

18. The nutritional composition for use according to claims 10 to 17, wherein the nutritional composition is administered to a human subject with a high exposure to xenobiotic or harmful endogenous substances.

Citation Information

Patent Citations

  • Lactobacillus metabolite as well as preparation method and application thereof

    CN114317621A

  • Preparation of galacto-oligosaccharide and beta-galactosidase enriched products fermented using streptococcus thermophilus

    EP0778885A1

  • High-density polyethylene compositions, method of making the same, articles made therefrom, and method of making such articles

    EP2016127A2

  • Prodn. of Streptococcus thermophilus cultures rich in beta-galactosidase

    FR2723960A1

  • Method for the production of an immunostimulant milk product and uses thereof

    US7410653B1